{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:37:18Z","timestamp":1794861438320,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["2016-1-PL BIO-07-1"],"award-info":[{"award-number":["2016-1-PL BIO-07-1"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["2016-1-PL BIO-07-1"],"award-info":[{"award-number":["2016-1-PL BIO-07-1"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EQUIPE LABELISEE"],"award-info":[{"award-number":["EQUIPE LABELISEE"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EQUIPE LABELISEE"],"award-info":[{"award-number":["EQUIPE LABELISEE"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Anaplastic large cell lymphoma positive for ALK (ALK+ ALCL) is a rare type of non-Hodgkin lymphoma. This lymphoma is caused by chromosomal translocations involving the anaplastic lymphoma kinase gene (ALK). In this study, we aimed to identify mechanisms of transformation and therapeutic targets by generating a model of ALK+ ALCL lymphomagenesis ab initio with the specific NPM-ALK fusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed CRISPR\/Cas9-mediated genome editing of the NPM-ALK chromosomal translocation in primary human activated T lymphocytes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both CD4+ and CD8+ NPM-ALK-edited T lymphocytes showed rapid and reproducible competitive advantage in culture and led to in vivo disease development with nodal and extra-nodal features. Murine tumors displayed the phenotypic diversity observed in ALK+ ALCL patients, including CD4+ and CD8+ lymphomas. Assessment of transcriptome data from models and patients revealed global activation of the WNT signaling pathway, including both canonical and non-canonical pathways, during ALK+ ALCL lymphomagenesis. Specifically, we found that the WNT signaling cell surface receptor ROR2 represented a robust and genuine marker of all ALK+ ALCL patient tumor samples.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, ab initio modeling of the ALK+ ALCL chromosomal translocation in mature T lymphocytes enabled the identification of new therapeutic targets. As ROR2 targeting approaches for other cancers are under development (including lung and ovarian tumors), our findings suggest that ALK+ ALCL cases with resistance to current therapies may also benefit from ROR2 targeting strategies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12943-022-01520-0","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T06:02:49Z","timestamp":1646373769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Lo\u00e9lia","family":"Babin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Darchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakia","family":"Aid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"Borry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Soudais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Piganeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"De Cian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Giovannangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Bawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Scoazec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Couronn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla","family":"Veleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Cieslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Asnafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sibon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Meggetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mercher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-4673","authenticated-orcid":false,"given":"Erika","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"1520_CR1","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.3390\/cancers12102747","volume":"12","author":"L Mussolin","year":"2020","unstructured":"Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, et al. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020;12:2747.","journal-title":"Cancers (Basel)"},{"key":"1520_CR2","doi-asserted-by":"publisher","first-page":"e562","DOI":"10.3324\/haematol.2018.213512","volume":"104","author":"D Sibon","year":"2019","unstructured":"Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104:e562\u20135.","journal-title":"Haematologica"},{"key":"1520_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2017.06.026","volume":"83","author":"A Morel","year":"2017","unstructured":"Morel A, Bri\u00e8re J, Lamant L, Loschi M, Haioun C, Delarue R, et al. Long-term outcomes of adults with first-relapsed\/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA\/SFGM-TC study. Eur J Cancer. 2017;83:146\u201353.","journal-title":"Eur J Cancer"},{"key":"1520_CR4","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.2020009806","volume":"137","author":"EJ Lowe","year":"2021","unstructured":"Lowe EJ, Reilly AF, Lim MS, Gross TG, Saguilig L, Barkauskas DA, et al. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. Blood. 2021;137:3595\u2013603.","journal-title":"Blood"},{"key":"1520_CR5","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2017","unstructured":"Swerdlow S. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues; 2017."},{"key":"1520_CR6","doi-asserted-by":"publisher","first-page":"10087","DOI":"10.1038\/ncomms10087","volume":"7","author":"TI Malcolm","year":"2016","unstructured":"Malcolm TI, Villarese P, Fairbairn CJ, Lamant L, Trinquand A, Hook CE, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun. 2016;7:10087.","journal-title":"Nat Commun"},{"key":"1520_CR7","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.1172\/JCI134990","volume":"130","author":"A Congras","year":"2020","unstructured":"Congras A, Hoareau-Aveilla C, Caillet N, Tosolini M, Villarese P, Cieslak A, et al. ALK-transformed mature T lymphocytes restore early thymus progenitor features. J Clin Invest. 2020;130:6395\u2013408.","journal-title":"J Clin Invest"},{"key":"1520_CR8","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1158\/0008-5472.CAN-20-2297","volume":"81","author":"JM Pawlicki","year":"2021","unstructured":"Pawlicki JM, Cookmeyer DL, Maseda D, Everett JK, Wei F, Kong H, et al. NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation. Cancer Res. 2021;81:3241\u201354.","journal-title":"Cancer Res"},{"key":"1520_CR9","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1038\/sj.onc.1207703","volume":"23","author":"HM Amin","year":"2004","unstructured":"Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, et al. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene. 2004;23:5426\u201334.","journal-title":"Oncogene"},{"key":"1520_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm1249","volume":"11","author":"R Chiarle","year":"2005","unstructured":"Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med. 2005;11:623\u20139.","journal-title":"Nat Med"},{"key":"1520_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.onc.1205152","volume":"21","author":"A Zamo","year":"2002","unstructured":"Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21:1038\u201347.","journal-title":"Oncogene"},{"key":"1520_CR12","doi-asserted-by":"publisher","first-page":"7750","DOI":"10.1038\/sj.onc.1207048","volume":"22","author":"SD Turner","year":"2003","unstructured":"Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene. 2003;22:7750\u201361.","journal-title":"Oncogene"},{"key":"1520_CR13","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2002-05-1343","volume":"101","author":"R Chiarle","year":"2003","unstructured":"Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101:1919\u201327.","journal-title":"Blood"},{"key":"1520_CR14","first-page":"3191","volume":"25","author":"R Jager","year":"2005","unstructured":"Jager R, Hahne J, Jacob A, Egert A, Schenkel J, Wernert N, et al. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res. 2005;25:3191\u20136.","journal-title":"Anticancer Res"},{"key":"1520_CR15","first-page":"3275","volume":"26","author":"SD Turner","year":"2006","unstructured":"Turner SD, Merz H, Yeung D, Alexander DR. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy. Anticancer Res. 2006;26:3275\u20139.","journal-title":"Anticancer Res"},{"key":"1520_CR16","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1182\/blood-2008-06-163386","volume":"115","author":"S Giuriato","year":"2010","unstructured":"Giuriato S, Foisseau M, Dejean E, Felsher DW, Al Saati T, Demur C, et al. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma\/leukemia. Blood. 2010;115:4061\u201370.","journal-title":"Blood"},{"key":"1520_CR17","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.ajpath.2013.08.030","volume":"183","author":"Q Zhang","year":"2013","unstructured":"Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, et al. The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. Am J Pathol. 2013;183:1971\u201380.","journal-title":"Am J Pathol"},{"key":"1520_CR18","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1038\/onc.2015.456","volume":"35","author":"M Ceccon","year":"2016","unstructured":"Ceccon M, Merlo MEB, Mologni L, Poggio T, Varesio LM, Menotti M, et al. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2016;35:3854\u201365.","journal-title":"Oncogene"},{"key":"1520_CR19","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/0008-5472.CAN-20-3837","volume":"81","author":"A Sole","year":"2021","unstructured":"Sole A, Grosset\u00eate S, Heintz\u00e9 M, Babin L, Za\u00efdi S, Revy P, et al. Unraveling Ewing Sarcoma Tumorigenesis Originating from Patient-Derived Mesenchymal Stem Cells. Cancer Res. 2021;81:4994\u20135006.","journal-title":"Cancer Res"},{"key":"1520_CR20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jmoldx.2018.08.006","volume":"21","author":"C Derrieux","year":"2019","unstructured":"Derrieux C, Trinquand A, Bruneau J, Verkarre V, Lhermitte L, Alcantara M, et al. A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2019;21:111\u201322.","journal-title":"J Mol Diagn"},{"key":"1520_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-12-801185-0.00012-X","volume":"546","author":"B Renouf","year":"2014","unstructured":"Renouf B, Piganeau M, Ghezraoui H, Jasin M, Brunet E. Creating cancer translocations in human cells using Cas9 DSBs and nCas9 paired nicks. Methods Enzymol. 2014;546:251\u201371.","journal-title":"Methods Enzymol"},{"key":"1520_CR22","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.celrep.2016.02.018","volume":"14","author":"JB Renaud","year":"2016","unstructured":"Renaud JB, Boix C, Charpentier M, De Cian A, Cochennec J, Duvernois-Berthet E, et al. Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases. Cell Rep. 2016;14:2263\u201372.","journal-title":"Cell Rep"},{"key":"1520_CR23","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","volume":"159","author":"BL Levine","year":"1997","unstructured":"Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, et al. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol. 1997;159:5921\u201330.","journal-title":"J Immunol"},{"key":"1520_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.molcel.2014.08.002","volume":"55","author":"H Ghezraoui","year":"2014","unstructured":"Ghezraoui H, Piganeau M, Renouf B, Renaud JB, Sallmyr A, Ruis B, et al. Chromosomal translocations in human cells are generated by canonical nonhomologous end-joining. Mol Cell. 2014;55:829\u201342.","journal-title":"Mol Cell"},{"key":"1520_CR25","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/sj.leu.2403840","volume":"19","author":"GZ Rassidakis","year":"2005","unstructured":"Rassidakis GZ, Thomaides A, Wang S, Jiang Y, Fourtouna A, Lai R, et al. p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia. 2005;19:1663\u20139.","journal-title":"Leukemia"},{"key":"1520_CR26","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Mosse","year":"2017","unstructured":"Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017;35:3215\u201321.","journal-title":"J Clin Oncol"},{"key":"1520_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1309\/HEFL7KC435KFWEX8","volume":"119","author":"J Juco","year":"2003","unstructured":"Juco J, Holden JT, Mann KP, Kelley LG, Li S. Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry. Am J Clin Pathol. 2003;119:205\u201312.","journal-title":"Am J Clin Pathol"},{"key":"1520_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2020.01.005","volume":"98","author":"J Shen","year":"2020","unstructured":"Shen J, Medeiros LJ, Li S, Wang SA, Lin P, Khanlari M, et al. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Hum Pathol. 2020;98:1\u20139.","journal-title":"Hum Pathol"},{"key":"1520_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/RRS-120018757","volume":"23","author":"A Yoda","year":"2003","unstructured":"Yoda A, Oishi I, Minami Y. Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans. J Recept Signal Transduct Res. 2003;23:1\u201315.","journal-title":"J Recept Signal Transduct Res"},{"key":"1520_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cells10010142","volume":"10","author":"K Menck","year":"2021","unstructured":"Menck K, Heinrichs S, Baden C, Bleckmann A. The WNT\/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells. 2021;10:142.","journal-title":"Cells"},{"key":"1520_CR31","doi-asserted-by":"publisher","first-page":"631623","DOI":"10.3389\/fcell.2021.631623","volume":"9","author":"Y Azbazdar","year":"2021","unstructured":"Azbazdar Y, Karabicici M, Erdal E, Ozhan G. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer. Front Cell Dev Biol. 2021;9:631623.","journal-title":"Front Cell Dev Biol"},{"key":"1520_CR32","doi-asserted-by":"publisher","first-page":"110946","DOI":"10.1016\/j.biopha.2020.110946","volume":"133","author":"Y Chen","year":"2021","unstructured":"Chen Y, Chen Z, Tang Y, Xiao Q. The involvement of noncanonical Wnt signaling in cancers. Biomed Pharmacother. 2021;133:110946.","journal-title":"Biomed Pharmacother"},{"key":"1520_CR33","doi-asserted-by":"crossref","unstructured":"Gajos-Michniewicz A, Czyz M. WNT Signaling in Melanoma. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21144852"},{"key":"1520_CR34","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-020-01276-5","volume":"19","author":"X Xu","year":"2020","unstructured":"Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19:165.","journal-title":"Mol Cancer"},{"key":"1520_CR35","doi-asserted-by":"publisher","first-page":"109636","DOI":"10.1016\/j.cellsig.2020.109636","volume":"72","author":"E Flores-Hernandez","year":"2020","unstructured":"Flores-Hernandez E, Velazquez DM, Castaneda-Patlan MC, Fuentes-Garcia G, Fonseca-Camarillo G, Yamamoto-Furusho JK, et al. Canonical and non-canonical Wnt signaling are simultaneously activated by Wnts in colon cancer cells. Cell Signal. 2020;72:109636.","journal-title":"Cell Signal"},{"key":"1520_CR36","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-016-0349-z","volume":"9","author":"C Wu","year":"2016","unstructured":"Wu C, Zhang HF, Gupta N, Alshareef A, Wang Q, Huang YH, et al. A positive feedback loop involving the Wnt\/\u03b2-catenin\/MYC\/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. J Hematol Oncol. 2016;9:120.","journal-title":"J Hematol Oncol"},{"key":"1520_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u20135.","journal-title":"Nature"},{"key":"1520_CR38","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","volume":"25","author":"JJ Luke","year":"2019","unstructured":"Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT\/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019;25:3074\u201383.","journal-title":"Clin Cancer Res"},{"key":"1520_CR39","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s12276-020-0380-6","volume":"52","author":"YS Jung","year":"2020","unstructured":"Jung YS, Park JI. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond beta-catenin and the destruction complex. Exp Mol Med. 2020;52:183\u201391.","journal-title":"Exp Mol Med"},{"key":"1520_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1349-7006.2009.01165.x","volume":"100","author":"K Morioka","year":"2009","unstructured":"Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227\u201333.","journal-title":"Cancer Sci"},{"key":"1520_CR41","doi-asserted-by":"crossref","unstructured":"Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, von der Brelie C, et al: WNT11 is a novel ligand for ROR2 in human breast cancer. bioRxiv 2020:2020.2012.2018.423402.","DOI":"10.1101\/2020.12.18.423402"},{"key":"1520_CR42","doi-asserted-by":"publisher","first-page":"e1002428","DOI":"10.1371\/journal.pgen.1002428","volume":"7","author":"DJ Laird","year":"2011","unstructured":"Laird DJ, Altshuler-Keylin S, Kissner MD, Zhou X, Anderson KV. Ror2 enhances polarity and directional migration of primordial germ cells. PLoS Genet. 2011;7:e1002428.","journal-title":"PLoS Genet"},{"key":"1520_CR43","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1534\/genetics.104.031781","volume":"168","author":"WC Forrester","year":"2004","unstructured":"Forrester WC, Kim C, Garriga G. The Caenorhabditis elegans Ror RTK CAM-1 inhibits EGL-20\/Wnt signaling in cell migration. Genetics. 2004;168:1951\u201362.","journal-title":"Genetics"},{"key":"1520_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/onc.2009.305","volume":"29","author":"MP O'Connell","year":"2010","unstructured":"O'Connell MP, Fiori JL, Xu M, Carter AD, Frank BP, Camilli TC, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29:34\u201344.","journal-title":"Oncogene"},{"key":"1520_CR45","doi-asserted-by":"publisher","first-page":"13115","DOI":"10.18632\/aging.103400","volume":"12","author":"M Guo","year":"2020","unstructured":"Guo M, Ma G, Zhang X, Tang W, Shi J, Wang Q, et al. ROR2 knockdown suppresses breast cancer growth through PI3K\/ATK signaling. Aging (Albany NY). 2020;12:13115\u201327.","journal-title":"Aging (Albany NY)"},{"key":"1520_CR46","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1038\/onc.2017.206","volume":"36","author":"K Roarty","year":"2017","unstructured":"Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 2017;36:5958\u201368.","journal-title":"Oncogene"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01520-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01520-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T10:05:19Z","timestamp":1674900319000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01520-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1520"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01520-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was approved by the INSERM CEEI\/IRB ethics committee (Avis n\u00b020\u2013664). PBMCs were isolated from healthy donor blood (under agreement EFS C CPSL UNT N\u00b0 20\/EFS\/005). Animal care and use for this study were performed in accordance with the recommendations of the European Community (2010\/63\/UE) for the care and use of laboratory animals. All experiments were approved by the French National Animal Care and Use Committee (CEEA 26: #2017122111548235_v2, the Gustave Roussy preclinical facility, Villejuif, France). All experiments were approved by the French National Animal Care and Use Committee (APAFlS# 6725\u20132016091415495765-v8, CRCT Toulouse France). The use of tissue samples has been approved by our institutional ethics committee (patient collection samples: DC-2020-4074; AC-2020-4031 (CRB of CHU Toulouse)).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The following authors (EB, TM, LB, ER, AD, FM and LL) declare a European patent application for \u201cMethods For The Treatment Of Anaplastic Large Cell Lymphoma\u201d (reference: BRUNET21072MC\/ BTL, April 9, 2021, application number EP21305467, applicants INSERM, and IMAGINE Institute, France).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}